A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics

Nature Chemical Biology

Volumn 10, Issue 10, 2014, Pages 853-860

  Chaikuad, Apirat ^a   Tacconi, Eliana M C ^a   Zimmer, Jutta ^a   Liang, Yanke ^b   Gray, Nathanael S ^b   Tarsounas, Madalena ^a   Knapp, Stefan ^a,c,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JNK1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN; PYRIMIDINE DERIVATIVE; SCH 772984; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GSG2 PROTEIN, HUMAN; INDAZOLE DERIVATIVE; MAPK1 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; SCH772984; SIGNAL PEPTIDE; STRESS ACTIVATED PROTEIN KINASE 1;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER CELL LINE; CONTROLLED STUDY; DRUG BINDING; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METABOLISM; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 8; PIPERAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS;

EID: 84921278792     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1629     Document Type: Article

References (58)

1. Chang, L., Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37-40 (2001).
2. Hatzivassiliou, G. et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature 501, 232-236 (2013).
3. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
4. Whittaker, S.R. et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350-362 (2013).
5. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
6. Joseph, E.W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903-14908 (2010).
7. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
8. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
9. Corcoran, R.B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
10. Brady, D.C. et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509, 492-496 (2014).
11. Poulikakos, P.I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAFV600E. Nature 480, 387-390 (2011).
12. Flaherty, K.T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
13. Hatzivassiliou, G. et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11, 1143-1154 (2012).
14. Ohori, M. et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 336, 357-363 (2005).
15. Aronov, A.M. et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362-6368 (2009).
16. Zhao, Z. et al. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9, 1230-1241 (2014).
17. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).
18. Hari, S.B., Merritt, E.A., Maly, D.J. Sequence determinants of a specific inactive protein kinase conformation. Chem. Biol. 20, 806-815 (2013).
19. Morris, E.J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
20. Zhang, F., Strand, A., Robbins, D., Cobb, M.H., Goldsmith, E.J. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 367, 704-711 (1994).
21. Canagarajah, B.J., Khokhlatchev, A., Cobb, M.H., Goldsmith, E.J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90, 859-869 (1997).
22. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
23. Eswaran, J. et al. Structure and functional characterization of the atypical human kinase haspin. Proc. Natl. Acad. Sci. USA 106, 20198-20203 (2009).
24. Fedorov, O., Niesen, F.H., Knapp, S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol. Biol. 795, 109-118 (2012).
25. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523-20528 (2007).
26. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
27. Fox, T. et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7, 2249-2255 (1998).
28. Kinoshita, T. et al. Crystal structure of human mono-phosphorylated ERK1 at Tyr204. Biochem. Biophys. Res. Commun. 377, 1123-1127 (2008).
29. Gruenbaum, L.M. et al. Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem. Pharmacol. 77, 422-432 (2009).
30. Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9, 268-272 (2002).
31. Bullock, A.N. et al. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure 17, 352-362 (2009).
32. Chaikuad, A. et al. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochem. J. 459, 59-69 (2014).
33. Lucet, I.S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183 (2006).
34. Kwiatkowski, N. et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat. Chem. Biol. 6, 359-368 (2010).
35. Carlos, A.R. et al. ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. Nat. Commun. 4, 2697 (2013).
36. Kraakman-van der Zwet, M. et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell. Biol. 22, 669-679 (2002).
37. Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925 (2008).
38. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
39. Polo, S.E., Jackson, S.P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 25, 409-433 (2011).
40. Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529-542 (2011).
41. Hashimoto, Y., Ray Chaudhuri, A., Lopes, M., Costanzo, V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat. Struct. Mol. Biol. 17, 1305-1311 (2010).
42. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006).
43. Guimarães, C.R. et al. Understanding the impact of the P-loop conformation on kinase selectivity. J. Chem. Inf. Model. 51, 1199-1204 (2011).
44. Hari, S.B., Perera, B.G., Ranjitkar, P., Seeliger, M.A., Maly, D.J. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. ACS Chem. Biol. 8, 2734-2743 (2013).
45. Copeland, R.A., Pompliano, D.L., Meek, T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006).
46. Swinney, D.C. The role of binding kinetics in therapeutically useful drug action. Curr. Opin. Drug Discov. Devel. 12, 31-39 (2009).
47. Selzer, T., Albeck, S., Schreiber, G. Rational design of faster associating and tighter binding protein complexes. Nat. Struct. Biol. 7, 537-541 (2000).
48. Schmidtke, P., Luque, F.J., Murray, J.B., Barril, X. Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. J. Am. Chem. Soc. 133, 18903-18910 (2011).
49. Keates, T. et al. Expressing the human proteome for affinity proteomics: optimising expression of soluble protein domains and in vivo biotinylation. N. Biotechnol. 29, 515-525 (2012).
50. Battye, T.G., Kontogiannis, L., Johnson, O., Powell, H.R., Leslie, A.G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011).
51. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72-82 (2006).
52. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
53. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
54. Oza, V. et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J. Med. Chem. 55, 5130-5142 (2012).
55. Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
56. Murshudov, G.N., Vagin, A.A., Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
57. Painter, J., Merritt, E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450 (2006).
58. Davis, I.W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).